Descriptors
Documents disponibles dans cette catégorie (116)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Extend search on down-posting(s)
2011 Survey of Health Care Consumers Global Report / Deloitte Center for Health Solutions / Deloitte Development (2011)
ACC/AHA Joint Guidelines [electronic document] . - American Heart Association, 2014.
Languages : English (eng)
Descriptors: Classification
W 84 Health services. Quality of health care (General)
Indexation
Cardiology ; Cardiovascular diseases ; Practice Guideline, Publishers' catalogue ; United StatesAbstract: The American Heart Association and American Stroke Association publish medical scientific statements on various cardiovascular disease and stroke topics. AHA/ASA volunteer scientists and healthcare professionals write the statements. The statements are supported by scientific studies published in recognized journals and have a rigorous review and approval process. Scientific statements generally include a review of data available on a specific subject, an evaluation on its relationship to overall cardiovascular disease science, and often an AHA/ASA position on the basis of that evaluation. Link for e-copy: http://my.americanheart.org/professional/StatementsGuidelines/ByTopic/TopicsA-C/ [...] Format of e-copy: Online [Free] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3426 Adult obesity and number of years lived with and without cardiovascular disease / M.C. Pardo Silva in Obesity, 14(2006)7 ([07/01/2006])
[article] Adult obesity and number of years lived with and without cardiovascular disease [printed text] / M.C. Pardo Silva, Author ; Chris De Laet , Author ; W.J. Nusselder, Author ; A.A. Mamun, Author ; A. Peeters, Author . - 2006 . - 1264-73.
Languages : English (eng)
in Obesity > 14(2006)7 [07/01/2006] . - 1264-73
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Aging ; Body Mass Index ; Cardiovascular diseases ; Cost of Illness ; Female ; Humans ; Journal Article ; Life Expectancy ; Male ; Middle Aged ; Myocardial infarction ; Obesity ; Overweight ; Peer Review ; Risk Assessment ; Risk Factors ; Stroke ; Time Factors ; United StatesAbstract: OBJECTIVE: To determine the differences in number of years lived free of cardiovascular disease (CVD) and number of years lived with CVD between men and women who were obese, pre-obese, or normal weight at 45 years of age.
RESEARCH METHODS AND PROCEDURES: We constructed multistate life tables for CVD, myocardial infarction, and stroke, using data from 2551 enrollees (1130 men) in the Framingham Heart Study who were 45 years of age.
RESULTS: Obesity and pre-obesity were associated with fewer number of years free of CVD, myocardial infarction, and stroke and an increase in the number of years lived with these diseases. Forty-five-year-old obese men with no CVD survived 6.0 years [95% confidence interval (CI), 4.1; 8.1] fewer than their normal weight counterparts, whereas, for women, the difference between obese and normal weight subjects was 8.4 years (95% CI: 6.2; 10.8). Obese men and women lived with CVD 2.7 (95% CI: 1.0; 4.4) and 1.4 years (95% CI: -0.3; 3.2) longer, respectively, than normal weight individuals.
DISCUSSION: In addition to reducing life expectancy, obesity before middle age is associated with a reduction in the number of years lived free of CVD and an increase in the number of years lived with CVD. Such information is paramount for preventive and therapeutic decision-making by individuals and practitioners alike.Link for e-copy: http://www.nature.com/oby/journal/v14/n7/pdf/oby2006144a.pdf Format of e-copy: PDF [Open Access] (Embargo 2 years) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2154 [article]
Adverse Effects of Vaccines : Evidence and Causality [printed text] / Kathleen Stratton, Author ; Andrew Ford, Author ; Erin Rusch, Author ; Ellen Wright Clayton, Author . - Washington, D.C. : National Academy Press, 2011 . - 800 p. : ill. ; A5.
ISBN : 978-0-309-21435-3 : $ 72,86
Languages : English (eng)
Descriptors: Indexation
Electronic books ; Encephalitis, Varicella Zoster ; Epidemiology ; Evidence-Based Practice ; Influenza Vaccines ; Papillomavirus Vaccines ; United States ; Vaccines
Classification
QW 805 Vaccines. Antitoxins. ToxoidsAbstract:
In 1900, for every 1000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The cornerstone of the vaccine safety system in the United States is the National Childhood Vaccine Injury Act. This legislation was intended to bolster vaccine research and development through federal coordination of vaccine initiatives, and by providing relief to vaccine manufacturers facing financial burdens. A key component of the legislation required the Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse effects, especially in children.
The Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health effects associated with specific vaccines covered by the Vaccine Injury Compensation Program including varicella zoster vaccine, influenza vaccines, hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews prior studies, summarizes their findings, and evaluates the epidemiological evidence. It finds that while no vaccine is 100% safe, very few adverse events are shown to be caused by vaccines.
In addition, the evidence shows that vaccines do not cause several conditions of recent concern. For example, the MMR vaccine is not associated with autism or childhood diabetes. The DTaP vaccine is also not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. The Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.Contents note:
SUMMARY 1 -- Charge to the Committee 2 -- Assessing the Weight of Evidence 2 -- Causality Assessment 5 -- Causality Conclusions 7 -- Susceptibility 9 -- Concluding Comment 9 -- References 24 -- 1 INTRODUCTION 25 -- Charge to the Committee 27 -- Committee Process 28 -- Outline of the Report 28 -- References 33 -- 2 APPROACH 35 -- Literature Searching 35 -- Weight of Evidence 36 -- Causality Assessment 41 -- Special Considerations 45 -- References 48 -- 3 EVALUATING BIOLOGICAL MECHANISMS OF ADVERSE EVENTS 51 -- Latency Between Antigen Exposure and Peak Adaptive Immune Response 51 -- Immune-Mediated Mechanisms 52 -- Viral Activity 66 -- Injection-Related Adverse Events 67 -- Coagulation and Hypercoagulable States 69 -- Increased Susceptibility 70 -- Alterations in Brain Development 73 -- Contribution of Animal Models 76 -- References 79 -- 4 MEASLES, MUMPS, AND RUBELLA VACCINE 89 -- Introduction 89 -- Measles Inclusion Body Encephalitis 93 -- Encephalitis and Encephalopathy 95 -- Febrile Seizures 100 -- Afebrile Seizures 105 -- Meningitis 107 -- Ataxia 110 -- Autism 112 -- Acute Disseminated Encephalomyelitis 115 -- Transverse Myelitis 116 -- Optic Neuritis 117 -- Neuromyelitis Optica 119 -- Multiple Sclerosis Onset in Adults 120 -- Multiple Sclerosis Onset in Children 122 -- Guillain-Barré Syndrome 123 -- Chronic Inflammatory Disseminated Polyneuropathy 124 -- Opsoclonus Myoclonus Syndrome 125 -- Brachial Neuritis 125 -- Anaphylaxis 126 -- Transient Arthralgia in Women 130 -- Transient Arthralgia in Children 134 -- Chronic Arthralgia in Women 137 -- Chronic Arthritis in Women 140 -- Chronic Arthropathy in Children 143 -- Arthropathy in Men 144 -- Type 1 Diabetes 146 -- Hepatitis 149 -- Chronic Fatigue Syndrome 150 -- Fibromyalgia 151 -- Hearing Loss 151 -- References 196 -- 5 VARICELLA VIRUS VACCINE 211 -- Introduction 211 -- Disseminated Oka VZV Without Other Organ Involvement 213 -- Disseminated Oka VZV with Other Organ Involvement 219 -- Vaccine Strain Viral Reactivation Without Other Organ Involvement 224 -- Vaccine Strain Viral Reactivation with Other Organ Involvement 228 -- Encephalopathy 233 -- Seizures 233 -- Cerebellar Ataxia 235 -- Acute Disseminated Encephalomyelitis 236 -- Transverse Myelitis 237 -- Guillain-Barré Syndrome 238 -- Small Fiber Neuropathy 239 -- Anaphylaxis 239 -- Onset or Exacerbation of Arthropathy 242 -- Stroke 243 -- Thrombocytopenia 244 -- References 248 -- 6 INFLUENZA VACCINE 257 -- Introduction 257 -- Encephalitis and Encephalopathy 262 -- Seizures 264 -- Acute Disseminated Encephalomyelitis 267 -- Optic Neuritis 269 -- Neuromyelitis Optica 271 -- Multiple Sclerosis Onset in Adults 271 -- Multiple Sclerosis Relapse in Adults 273 -- Guillain-Barré Syndrome 275 -- Chronic Inflammatory Disseminated Polyneuropathy 281 -- Bell’s Palsy 282 -- Brachial Neuritis 284 -- Small Fiber Neuropathy 285 -- Anaphylaxis 285 -- Inactivated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children and Adults 288 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children Younger Than 5 Years of Age 293 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Persons 5 Years of Age or Older 298 -- Onset or Exacerbation of Systemic Lupus Erythematosus 301 -- Onset or Exacerbation of Vasculitis 304 -- Polyarteritis Nodosa 306 -- Onset or Exacerbation of Arthropathy 307 -- Stroke 308 -- Myocardial Infarction 309 -- Fibromyalgia 311 -- All-Cause Mortality 311 -- Oculorespiratory Syndrome 313 -- References 354 -- 7 HEPATITIS A VACCINE 369 -- Introduction 369 -- Acute Disseminated Encephalomyelitis 370 -- Transverse Myelitis 371 -- Multiple Sclerosis 372 -- Guillain-Barré Syndrome 373 -- Chronic Inflammatory Disseminated Polyneuropathy 374 -- Bell’s Palsy 374 -- Anaphylaxis 375 -- Autoimmune Hepatitis 376 -- References 378 -- 8 HEPATITIS B VACCINE 381 -- Introduction 381 -- Encephalitis and Encephalopathy 383 -- Seizures 383 -- Acute Disseminated Encephalomyelitis 385 -- Transverse Myelitis 386 -- Optic Neuritis 387 -- Neuromyelitis Optica 389 -- Multiple Sclerosis Onset in Adults 390 -- Multiple Sclerosis Onset in Children 392 -- Multiple Sclerosis Relapse in Adults 394 -- Multiple Sclerosis Relapse in Children 395 -- First Demyelinating Event in Adults 396 -- First Demyelinating Event in Children 399 -- Guillain-Barré Syndrome 400 -- Chronic Inflammatory Disseminated Polyneuropathy 401 -- Brachial Neuritis 402 -- Anaphylaxis 402 -- Erythema Nodosum 403 -- Onset or Exacerbation of Systemic Lupus Erythematosus 404 -- Onset or Exacerbation of Vasculitis 406 -- Onset or Exacerbation of Polyarteritis Nodosa 409 -- Onset or Exacerbation of Psoriatic Arthritis 411 -- Onset or Exacerbation of Reactive Arthritis 412 -- Onset or Exacerbation of Rheumatoid Arthritis 414 -- Onset or Exacerbation of Juvenile Idiopathic Arthritis 416 -- Type 1 Diabetes 418 -- Fibromyalgia 420 -- References 431 -- 9 HUMAN PAPILLOMAVIRUS VACCINE 441 -- Introduction 441 -- Acute Disseminated Encephalomyelitis 442 -- Transverse Myelitis 443 -- Neuromyelitis Optica 444 -- Multiple Sclerosis 444 -- Guillain-Barré Syndrome 445 -- Chronic Inflammatory Disseminated Polyneuropathy 446 -- Brachial Neuritis 447 -- Amyotrophic Lateral Sclerosis 447 -- Anaphylaxis 449 -- Transient Arthralgia 450 -- Pancreatitis 451 -- Thromboembolic Events 452 -- Hypercoagulable States 453 -- References 455 -- 10 DIPHTHERIA TOXOID-, TETANUS TOXOID-, AND ACELLULAR PERTUSSISCONTAINING -- VACCINES 457 -- Introduction 457 -- Encephalitis and Encephalopathy 461 -- Infantile Spasms 464 -- Seizures 465 -- Ataxia 468 -- Autism 468 -- Acute Disseminated Encephalomyelitis 469 -- Transverse Myelitis 470 -- Optic Neuritis 471 -- Multiple Sclerosis Onset in Adults 472 -- Multiple Sclerosis Relapse in Adults 474 -- Multiple Sclerosis Relapse in Children 476 -- Guillain-Barré Syndrome 477 -- Chronic Inflammatory Disseminated Polyneuropathy 478 -- Opsoclonus Myoclonus Syndrome 480 -- Bell’s Palsy 480 -- Anaphylaxis 482 -- Chronic Urticaria 483 -- Serum Sickness 484 -- Arthropathy 485 -- Type 1 Diabetes 487 -- Myocarditis 490 -- Fibromyalgia 491 -- Sudden Infant Death Syndrome 491 -- Immune Thrombocytopenic Purpura 492 -- References 506 -- 11 MENINGOCOCCAL VACCINE 515 -- Introduction 515 -- Encephalitis and Encephalopathy 517 -- Acute Disseminated Encephalomyelitis 518 -- Transverse Myelitis 519 -- Multiple Sclerosis 519 -- Guillain-Barré Syndrome 520 -- Chronic Inflammatory Disseminated Polyneuropathy 521 -- Anaphylaxis 522 -- Chronic Headache 523 -- References 526 -- 12 INJECTION-RELATED ADVERSE EVENTS 529 -- Complex Regional Pain Syndrome 529 -- Deltoid Bursitis 531 -- Syncope 533 -- References 538 -- 13 CONCLUDING COMMENTS 541 -- References 545Link for e-copy: http://www.nap.edu/catalog.php?record_id=13164 Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2712 Age-related changes in human blood lymphocyte subpopulations / F. Erkeller-Yuksel in The Journal of Pediatrics, 120(1996)2 ([02/01/1996])
[article] Age-related changes in human blood lymphocyte subpopulations [printed text] / F. Erkeller-Yuksel, Author ; V. Deneys, Author ; B. Yuksel, Author ; I. Hannet, Author ; Frank Hulstaert, Author ; C. Hamilton, Author . - 1996 . - 216-222.
Languages : English (eng)
in The Journal of Pediatrics > 120(1996)2 [02/01/1996] . - 216-222
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Adolescent ; Adult ; Aged ; Aging ; Antigens, CD ; Child ; Child, Preschool ; Female ; Fetal Blood ; Humans ; Immunophenotyping ; Infant ; Journal Article ; Leukocyte Count ; Lymphocyte Subsets ; Male ; Middle Aged ; Peer Review ; United StatesAbstract: Flow cytometric analysis of major lymphocyte populations and their subsets reveals age-related changes in the cellular human immune system. Immunophenotypic markers were evaluated in 110 normal pediatric subjects, divided into groups of newborn infants, infants aged 2 days to 11 months, and children aged 1 to 6 years and 7 to 17 years; results were then compared with those obtained from 101 normal adults aged 18 to 70 years. Comparisons among age groups from newborn infants through adults reveal progressive declines in the absolute numbers of leukocytes, total lymphocytes, and T, B, and natural killer (NK) cells. The percentages of T cells within the total lymphocyte population increase with age, in both CD4+ and CD8+ subsets. Percentages of B and NK cells are higher in newborn infants than in adults. The expression of the activation markers interleukin-2R and HLA-DR on T cells increases with age, as does the NK-associated expression of CD57 on CD8 cells. The proportions of B lymphocytes that coexpress CD5 or CDw78 decrease with age, whereas expression of Leu-8 and CD23 increases. The proportion of CD4 cells bearing the CD45RA and Leu-8 markers is consistently lower in adults than in children. These data may serve as a reference range for studies of pediatric subjects. Link for e-copy: http://www.sciencedirect.com/science/journal/00223476 Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2187 [article]Age-related changes in human blood lymphocyte subpopulations / Frank Hulstaert in Clinical immunology and immunopathology, 70(1994)02 ([02/01/1994])
PermalinkPermalinkAlendronate or alfacalcidol in glucocorticoid-induced osteoporosis / R.N. de Nijs in The New England journal of medicine, 355(2006)7 ([08/17/2006])
PermalinkAll Patient Refined Diagnosis Related Groups (APR-DRGs) / Richard F. Averill / Wallingford [United States of America] : 3M Health Information Systems (1998)
PermalinkPermalinkAmerican Journal of Tropical Medicine and Hygiene / James W. Kazura / Deerfield, IL [United States] : American Society of Tropical Medicine and Hygiene (ASTMH) (1952)
PermalinkPermalinkAre thrombolytic drugs not evidence-based medications? / Hans Van Brabandt in Archives of Internal Medicine, 168(2008)2 ([01/28/2008])
PermalinkPermalinkPermalink